Weak Earnings, Silent Pipeline: Chong Kun Dang Pharmaceutical Bets on CAR-T and ADC for Comeback
Chong Kun Dang Pharmaceutical Corp., once in the spotlight for a blockbuster licensing deal worth KRW 1.7 trillion…
Synaffix
1 개의 기사가 있습니다.